# Effect of Entecavir Treatment on Regression and Disease Outcome in HBV-induced Liver Fibrosis and Cirrhosis Patients

> **NCT02849132** · PHASE4 · UNKNOWN · sponsor: **Beijing Friendship Hospital** · enrollment: 800 (estimated)

## Conditions studied

- Hepatitis B
- Liver Cirrhosis

## Interventions

- **DRUG:** Entecavir

## Key facts

- **NCT ID:** NCT02849132
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01
- **Primary completion:** 2023-12
- **Final completion:** 2025-12
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2021-04-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02849132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02849132, "Effect of Entecavir Treatment on Regression and Disease Outcome in HBV-induced Liver Fibrosis and Cirrhosis Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02849132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*